Three different receptors for the Fc portion of IgG (FcR) have been characterized on human leukocytes. We have identified four healthy members of one family, whose blood phagocytic cells lack functional 72 kD high-affinity FcRI. Their monocytes were unable to bind the Fc portion of mouse (m)-IgG2a and of monomeric human IgG, and they were unreactive with two anti-FcRI monoclonal antibodies. Thus, FcRI is either absent, expressed at very low density, or is so structurally altered as to be unable to bind both its ligand and the anti-FcRI antibodies. The failure to bind the Fc portion of mIgG2a underlies the previously reported inability of these monocytes to support T cell mitogenesis on OKT3 stimulation. FcRI was not inducible upon incubation of their monocytes or neutrophils in gamma interferon. However, their monocytes were able to bind aggregated human IgG, and to phagocytose IgG-coated particles in vitro. Both functions could be blocked with a monoclonal antibody to the 40-kD low-affinity FcRII and therefore apparently were mediated exclusively through FcRII. This also demonstrates that FcRII can mediate phagocytosis independently. Despite the FcRI defect, these subjects had no circulating immune complexes, no evidence of autoimmune pathology and no increased susceptibility to infections.
Introduction
Three distinct types of Fc receptors for IgG (FcR)' have been identified on human leukocytes (for review see 1) . A high affinity receptor (FcRI) of 72 kD is present on monocytes and macrophages (2) (3) (4) (5) (6) . Neutrophils express this receptor after overnight incubation in gamma-interferon (7) . A low affinity FcR (FcRII) of 40 kD (the CDw32 antigen) has a broader range of cellular expression, being present not only on mono-nuclear phagocytes but also on granulocytes, platelets, and B-lymphocytes (4, 8, 9) . A third type of FcR (FcRIII) (the CD16 antigen) has a molecular weight from 50 to 70 kD, is expressed by macrophages (but not monocytes), neutrophils, eosinophils (sparce), and subsets of lymphocytes (T-gamma cells and natural killer cells) (10) (11) (12) (13) . The 72-kD FcR binds monomeric human (Hu) IgGI and IgG3 with a Ka of 108-109 M', and 1-4 X 104 receptors are present per monocyte (5, 6) . In contrast HuIgG binds to FcRII only when it is present as a complex (either soluble complexes or IgG-coated particles) (4, 14) . The specificity of the monocytic receptors for murine (m) subclasses is quite distinctive. FcRI binds mIgG2a and mIgG3 with high affinity (4, 15) , while FcRII binds mIgG 1 and mIgG2b, although to be detected, binding must be enhanced by using low ionic strength conditions or ligand complexes (4, 14, 15) .
FcRs are important for the clearance of immune-complexes and for internalization ofIgG-coated cells or organisms. Defective FcR function has been associated with certain HLA-haplotypes and with immune complex disease susceptibility (16) (17) (18) . FcR triggering can stimulate cell metabolism, e.g., chemiluminescence of phagocytic cells (3) . Moreover, FcRs might be important for antigen presentation (19, 20) , and FcRs on phagocytic cells and NK cells are essential for extracellular killing in antibody-dependent cellular cytotoxicity (21, 22) . No functional differentiation between the distinct types of FcRs expressed on the same cell-type has been found yet and the relative importance ofthe three FcRs in mediating immunophagocytosis is not known.
We describe four healthy subjects, belonging to one kindred, apparently lacking functional FcRI. We have previously reported on these subjects as "OKT3 nonresponders," indicating the lack of proliferative T cell responses to the monoclonal anti-CD3 antibody OKT3 (and to other anti-CD3 antibodies of the mIgG2a subclass) in cultures of peripheral blood mononuclear cells (PBMC) (23, 24) . Unresponsiveness was observed in four among the seven children of one family and was not related to a particular HLA-haplotype (23) . The identification of these subjects was a fortuitous one, made while we were determining normal values for proliferative responses of PBMC to OKT3 on a large series ofhealthy donors. T cell stimulation in this system requires interactions of anti-CD3 with CGD3 on the T cell membrane and with monocyte FcRs (24, 25) . We reported that monocytes from nonresponders were unable to bind the Fc part of mIgG2a (24) and that this inability to bind mIgG2a underlies the inability ofthe monocytes to support mIgG2a anti-CD3-induced T-cell mitogenesis. We have now further explored this lack of mIgG2a binding to monocytes, and report here that it is based on a new and interesting defect of FcRI expression. The absence, low density expression, or afunctionality of this receptor is not associated with any disease. The significance ofthe FcRI defect remains to be determined.
Methods
Subjects. The four subjects, previously indentified as "OKT3 nonresponders" (23, 24) Before analysis, cells were washed and resuspended in one ml of PBS. They were then analyzed on a FACS-Star (Becton-Dickinson).
The gating was set around the monocyte or neutrophil population 4nd 5,000 cells were analyzed for fluorescence.
Binding ofradiolabeledHuIgG. Monomeric HuIgG (Cohn fraction II, 12 mg/ml, centrifuged for 30 min at 100,000 g) was labeled with 125I
by the chloramine T method to a specific activity of 4 ,Ci/Mg. The solution was centrifuged at 20,000 g to remove insoluble aggregates, the concentration was adjusted to 20 Mg/ml in PBS-BSA, and a twofold serial dilution was made. E-rosette negative cells (at a concentration of 10 to 15 X 106 peroxidase-positive cells per ml) in medium with 50%
FCS were preincubated in plastic tubes at 4°C with Ab IV.3 (in order to block FcRII). We then added '25I-gG in final concentrations of 6 to 0.37 ,ug/ml to the cell suspensions, and further incubated the mixture for 45 min at 4°C. Final cell concentration was 3-4.5 X 106 monocytes/ml. To determine nonspecific binding of '23I-IgG, part ofthe cells were incubated with cold IgG (6 mg/ml) before the radiolabeled ligand was added. Nonspecific binding represented < 0.01% ofthe total radioactivity. After extensive washing, radioactivity bound to the cells was determined.
Rosetting with anti-D coated human RBC. Human D-positive RBC were sensitized with human anti-D antiserum (Ortho Diagnostics) and resuspended as a 1% solution in HBSS. 200 Ml of the suspension was mixed with 100 Ml of E-rosette-negative cells (1 X 107 cells/ml), centrifuged at 100 g for 5 min, and incubated at 4°C for 60 min. In some experiments the E-rosette negative cells were preincubated with 20 Al of Ab IV.3 to block FcRII. After gentle resuspension, the number of rosette-forming monocytes was counted microscopically in a hemocytometer.
Monocyte phagocytosis assay. FcR-mediated phagocytosis by monocytes was evaluated by an assay similar to the one reported by Salmon et al. (17) . SRBC (108 cells/ml) were sensitized with a maximal subagglutinating dose of rabbit anti-SRBC antiserum (Behringwerke, Marburg, FRG). In some experiments, a twofold serial dilution of the antiserum was used to prepare SRBC that were suboptimally opsonized. To the mixture of SRBC and antiserum, 50 uCi of 5"Cr was added. After a 1-h incubation at 37°C, SRBC were washed in PBS and resuspended in culture medium with 10% FCS at a concentration of 108/ml. The (28) . Serum immune-complexes were detected by binding to solidphase Clq and monoclonal rheumatoid factor (mRF) as previously reported (29) . Serum immunoglobulines (A, G and M) were measured with a standard nephelometric immunioassay (Hyland Travenol Laboratories, Costa Mesa, CA). In vivo specific antibody production was studied by immunization with hepatitis B-surface antigen. Three injections ofthe commercial Pasteur vaccine (Hevac B) were given intramuscularly with a 1-mo interval, and a fourth (booster) injection was given 1 yr later. Antibody levels were determined with the commercially available RIA (Abbott Laboratories, North Chicago, IL).
Results
Nonresponder monocytes do not bind monomeric mIgG2a or HuIgG. We have reported (24) that monocytes from "OKT3-nonresponders" are unable to bind the Fc part of mIgG2a in an indirect immunofluorescence assay. We reexamined the FcR binding of mIgG2a to the monocytes with monomeric FITC-conjugated OKT3. Responder monocytes but not nonresponder monocytes were able to bind OKT3-FITC (not shown). Preincubation with unlabeled mIgG2a completely inhibited the binding of OKT3-FITC to the responder monocytes. In view of the reported specificity of the two distinct monocyte FcRs for mIgG subclasses (FcRI binds mIgG2a and FcRII binds mIgGI and mIgG2b) the results suggested that the A CONTROL SUBJECT defect in nonresponder-monocytes is at the level of FcRI. We also studied the interaction ofmonocytes with HuIgG. We first incubated the cells with FHTC-conjugated HuIgG. Monomeric HuIgG-FITC bound to responder monocytes, but not to nonresponder monocytes (Fig. 1) . Monomeric HuIgG has been shown to bind to FcRI only (1) (2) (3) (4) (5) (6) , and the lack ofbinding to nonresponder monocytes thus further argues for a defect of FcRI expression. Both responder and nonresponder monocytes were able to bind aggregated HuIgG-FITC (Fig. 1) . However, when the cells were incubated with decreasing doses of this ligand, the capacity of nonresponder monocytes to bind aggregated HuIgG-FITC was found to be lower than for responder monocytes (Fig. 1) . Binding of aggregated HuIgG-FITC was blocked by unlabeled aggregated HuIgG (not shown). Binding of aggregated HuIgG-FITC to nonresponder monocytes was also blocked with the anti-FcRII monoclonal antibody IV.3 (which has been shown to block the ligand interaction of FcRII (4)) (Fig. 2) . In contrast, Ab IV.3 only partially reduced the binding of aggregated HuIgG-FITC to responder monocytes. These results thus indicate that the binding of aggregated HuIgG to nonresponder monocytes is mediated exclusively through FcRII. Lack of binding of aggregated HuIgG to nonresponder monocytes in the presence of Ab IV.3 makes it unlikely that nonresponder subjects have a variant FcRI with low affinity for IgG. To detect low density expression of FcRI, a radiolabeled ligand binding assay was also used. Cells from two responders and two nonresponders were first incubated with AbIV.3 to block FcRII and then incubated with '25I-HuIgG in concentrations ranging from 6 to 0.37 jig/ml. (Fig. 4) . These results indicate that nonresponder monocytes either do not express FcRI, or express FcRI below the level of detection of our assay, or that they express an altered FcRI, which does not express the epitopes recognized by Ab 32.2 and 44.1. The receptor for G3bi on leucocytes (detected with monoclonal antibody OKM1), was found to be present in normal density on the monocytes and neutrophils from nonresponders. Similarly, a normal density of FcRIII was detected on neutrophils and NK-cells with the monoclonal antibody anti-Leu 1 lb (12). Monocytes from both responders and nonresponders lacked FcRIII. Both neutrophils and monocytes normally expressed the FcRII as detected with Ab IV.3 (not shown).
Gamma interferon does not induce FcRI expression on nonresponder monocytes or neutrophils. Gamma interferon has been shown to enhance the expression of FcRI on human monocytes (7, 31) . We therefore cultured E-rosette-negative cells (106/ml) for 48 h in Teflon jars, with or without gamma interferon (100 U/ml). Cells were then stained with the antiFcRI antibodies (Ab 32.2 and 44.1) in an indirect immunofluorescence assay. Gamma interferon did not induce FcRI in the nonresponder monocytes (Fig. 5) . Responder monocytes incubated in gamma interferon were stained more intensively with the anti-FcRI antibodies than monocytes incubated in medium alone. Similar results were obtained when monocytes were cultured for 7 Figure S . Gamma interferon does not induce FcRI expression in nonresponder monocytes. E-rosette-negative cells (106/ml) from control (responder) subjects and from OKT3-nonresponders were cultured in complete medium with 12% NHS for 48 h in Teflon jars, in the presence or absence of recombinant gamma interferon (100 U/ml). Cells were then washed and stained with Ab 32.2 and FITCconjugated F(ab')2 goat anti-mouse IgG (as explained in the legend to Fig. 4 ). Control monocytes incubated in gamma interferon expressed more FcRI than monocytes incubated in medium. However, nonresponder monocytes did not stain with anti-FcRI whether incubated in medium or in gamma interferon.
been shown to express FcRI after incubation for 18 h with gamma-interferon (7, 32) . After incubation overnight with 100 U/ml of gamma interferon, neutrophils from responders stained positively with both Ab 32.2 and 44.1, while neutrophils from the four nonresponders were completely negative (Fig. 6 ). These results demonstrate that the FcRI defect was not restricted to the mononuclear phagocyte lineage.
Phagocytosis ofIgG-coated SRBC. To study FcR-mediated phagocytosis, we incubated unopsonized or IgG-sensitized SRBC with monocytes from responder subjects and from nonresponders. As can be seen in Fig. 7 , the number of particles phagocytosed per monocyte per hour was not different between responders and nonresponders. Even at low SRBC/ monocyte ratios, or when the SRBC were opsonized with suboptimal doses of the antiserum, no difference between the two groups was detected (not shown). Ab IV.3 (anti-FcRII) almost completely blocked phagocytosis by nonresponder monocytes but not by responder monocytes (Fig. 8) . This indicates that in nonresponder monocytes, phagocytosis was completely mediated by FcRII, while in responders, both FcRI and FcRII were responsible for ingestion of the IgG-coated particles.
Effect of the FcRI defect on other immune functions. All four nonresponder subjects had normal serum levels of IgA, IgG, and IgM. None of them had circulating rheumatoid factors (Latex agglutination test), or anti-nuclear antibodies. Anti-thyroid cytoplasma antibodies were detected in low titer
(1/80) in the serum of one of the subjects, without evidence of thyroid dysfunction (normal T3 and T4 thyroid hormone and thyroid stimulating hormone levels). No antiparietal cell antibodies, antimitochondrial antibodies, antismooth-muscle antibodies or antistriped muscle antibodies were detected in any of the subjects. No circulating immune-complexes were detected. Peripheral blood lymphocytes normally proliferated in vitro in response to four different common exogeneous antigens (stimulation index > 10 to at least three of the four anti- (Table I) .
Discussion
The present paper describes a new defect of FcRI on phagocytic cells in four healthy subjects. Our previous reports on the unresponsiveness ofT cells to the monoclonal antibody OKT3 in cultures of PBMC from these subjects had already made it clear that their monocytes were unable to bind the Fc portion of mIgG2a (23, 24 The findings could be explained by a major mutational change in the structure of the receptor resulting in inability to bind IgG, and lack of expression of the epitopes recognized by Ab32.2 and 44.1. Alternatively, we might consider the possibility that the gene for FcRI is deleted or not expressed. We found that gamma-interferon did not induce FcRI expression in nonresponder monocytes, which argues against a regulatory defect in FcRI expression. Studies using the appropriate DNA-probes might help us to delineate more accurately the molecular basis of the FcRI defect.
Inability to bind mIgG2a in the nonresponder subjects underlies the lack of monocyte helper function in the support of mIgG2a anti-CD3 induced T cell mitogenesis. Indeed, interaction of anti-CD3 with both the CD3 molecule on the T cell, and with an FcR on the monocyte, is an essential requirement for T cell activation with anti-CD3 (25) . Until now these subjects are the only OKT3-nonresponders described, while unresponsiveness to mIgGl anti-CD3 antibodies (e.g., anti-Leu 4) is frequent (-30% of Caucasians). It has to be emphasized that the underlying defect of nonresponders to mIgG2a-anti-CD3 is quite different from that of mIgGl-anti-CD3 nonresponders. Monocytes of the latter group of nonresponders are unable to bind the Fc part of mIgGl to FcRII (34). This is not due to the absence of FcRII, but rather to a genetically determined dimorphism of the FcRII, as demonstrated by isoelectric focusing experiments on isolated FcRII molecules (35) . The alleles ofboth variants are about equally distributed in the population. Since only one of the two variant forms is able to bind mIgG I (while both can bind complexed HuIgG), homozygotes for the type of FcRII that is unable to bind mIgG1 will be nonresponders to mIgGl anti-CD3. This has no implications for their mononuclear phagocytic system in view of the apparent normal ability of this variant of FcRII to bind complexed HuIgG. The defective expression of phagocyte FcRI in the subjects described in this paper is thus a different situation. One would expect the absence of functional FcRI to be associated with a severe immune defect (16) (17) (18) (19) (20) (21) (22) . Surprisingly, these monocytes normally ingested (even suboptimally opsonized) IgG-coated SRBC, and this was exclusively mediated through FcRII, as demonstrated by the blocking experiments with Ab IV.3. Based on immunofluorescence intensity obtained with Ab IV.3, the density of FcRII did not appear to be increased on nonresponder monocytes. The monocytes (similar to control monocytes) also did not express detectable levels of FcRIII. Thus a compensatory increase in FcRII density or an unusual expression of FcRIII did not account for normal phagocytosis. The lack or functional incompetence of monocyte FcRI also has not resulted in any clinical pathology. No circulating immune complexes were detected, no autoimmune pathology was present, and the specific antibody response (primary and secondary) to a viral antigen were completely normal. These latter experiments were carried out in view of the data that FcRI might be involved in antigen presentation via membrane bound antibodies (19, 20 (36) . These results stress the dominant importance of FcRIII for removal of immune complexes in vivo. FcRIII is expressed on two types of phagocytic cells: neutrophils and macrophages (but not monocytes) (1 1). Moreover, complement receptors on the monocytes and the macrophages may also be important in the removal of immune complexes (37) . C3bi receptors, similar to FcRII and FcRIII receptors, are normally present on the phagocytic cell membranes of the four subjects described here. All this probably explains when they had normal immune function in spite of a major FcR defect, restricted however to only one type of FcR.
Apart from the description of a unique FcRI defect, our data also provide some additional information on monocyte FcR function. It has never been unequivocally demonstrated before that FcRII on monocytes can mediate phagocytosis of IgG-coated particles. This is due to inability ofblocking specifically FcRI function, while leaving FcRII intact. The results obtained with nonresponder monocytes now clearly demonstrate that FcRII indeed can mediate phagocytosis independently. The data also unequivocally demonstrate that normal FcRI function is required for binding of monomeric HuIgG and mIgG2a to monocytes, and that the cytophilic IgG on circulating monocytes from healthy subjects is fixed by FcRI. The findings should stimulate further work on the differential function and relative importance of the distinct types of FcRs on phagocytic cells.
